Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$115.38 USD

115.38
314,967

-2.75 (-2.33%)

Updated Sep 18, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Hold on to McKesson (MCK) Stock Now

McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.

Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet

Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag

Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y

The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.

BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test

BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.

Swayta Shah headshot

5 Top Ranked Stocks With Solid Sales Growth to Buy Right Now

Sales growth is an important indicator of a company's health and ability to sustain its business. Let's check Abbott (ABT), Facebook (FB), Stanley Black & Decker (SWK), Leidos (LDOS) & Euronet (EEFT) as these might witness solid sales growth.

TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows

TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.

Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.

Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.

DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates

DaVita's (DVA) bottomline in Q4 declines year over year.

DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis

In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat

Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.

HEXO Soars: Stock Adds 7.9% in Session

HEXO saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Here's Why Abbott (ABT) is a Great Momentum Stock to Buy

Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.